Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Vimseltinib for Patients with Tenosynovial Giant Cell Tumor

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition known as Tenosynovial Giant Cell Tumor (TGCT). TGCT is a type of tumor that affects the joints and can cause pain and stiffness. The study is testing a new treatment called Vimseltinib, which is taken as a capsule. The purpose of the study is to evaluate how effective and safe Vimseltinib is for patients with TGCT.

The study is divided into two parts. In the first part, participants will be randomly assigned to receive either Vimseltinib or a placebo, which looks like the medication but does not contain the active ingredient. This part of the study is double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication. In the second part, all participants will receive Vimseltinib, and this phase is open-label, meaning everyone will know they are receiving the medication.

Participants will take the medication orally and will be monitored over a period of time to assess the response of their tumor to the treatment. The study will also look at changes in joint movement, pain levels, and overall physical function. The goal is to see if Vimseltinib can reduce the size of the tumor and improve symptoms without causing significant side effects. The study will help determine if Vimseltinib is a viable treatment option for people with Tenosynovial Giant Cell Tumor.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the participant will be randomly assigned to receive either vimseltinib or a placebo. This is a double-blind study, meaning neither the participant nor the researchers will know which treatment is being administered during Part 1 of the study.

  2. Step 2

    Medication administration

    The participant will take the assigned medication orally in the form of a hard capsule. The specific dosage and frequency will be determined by the study protocol and communicated to the participant at the start of the trial.

  3. Step 3

    Monitoring and assessments

    Throughout the study, the participant will undergo regular assessments to monitor the response to the treatment. This includes imaging tests to evaluate tumor size and questionnaires to assess symptoms such as pain and stiffness.

    The primary goal is to measure the objective response rate at Week 25, which includes any complete or partial response to the treatment.

  4. Step 4

    Completion of Part 1

    At the end of Part 1, which lasts until Week 25, the participant's response to the treatment will be evaluated. This includes changes in joint function, pain levels, and overall health status.

  5. Step 5

    Transition to Part 2

    Part 2 of the study is open-label, meaning all participants will receive vimseltinib. The purpose of this phase is to continue monitoring the long-term effects and safety of the medication.

  6. Step 6

    Ongoing evaluations

    Participants will continue to have regular check-ups and assessments to track the duration of response and any side effects. This includes monitoring for any adverse events and changes in laboratory parameters.

  7. Step 7

    Study conclusion

    The study is expected to conclude by July 2026. At this point, all data will be analyzed to determine the overall efficacy and safety of vimseltinib for treating Tenosynovial Giant Cell Tumor.

Who can join the trial?

16 criteria

  • Participants must be **male or female** and **18 years of age or older**.
  • Participants who can have children must:
    • Have a **negative pregnancy test** at the start of the study (for females).
    • Agree to use **birth control** as described in the study plan.
    • Participants must understand and agree to follow the study rules and sign a **consent form** before starting any study-related activities.
    • Participants must be willing and able to complete **questionnaires** on an electronic device.
    • Participants must have a **confirmed diagnosis** of Tenosynovial Giant Cell Tumor (TGCT), which may require a **tumor biopsy** if previous test results are not available. The tumor should be in a single joint where **range of motion** can be checked.
    • The disease should be such that **surgery** could lead to worse movement problems or serious health issues, as determined by a doctor or a group of specialists.
    • Participants must have **symptoms** like moderate pain or stiffness, rated as a score of 4 or more out of 10, recorded during the screening period.
    • Participants must complete **14 days of questionnaires** during the screening period and meet the minimum requirements set in the study plan.
    • If participants are using **pain medication**, the dose must not change for at least 2 weeks before starting the study drug.
    • Participants must have a **measurable tumor** of at least 2 cm in size, as seen on an MRI scan.
    • Participants must have **adequate organ function** and bone marrow reserve, shown by specific lab tests done within 21 days before starting the study drug. This includes:
      • Bone marrow function: certain levels of blood cells and platelets.
      • Liver function: certain levels of bilirubin and liver enzymes.
      • Kidney function: a creatinine clearance of 50 mL/min or more.
      • Normal levels of electrolytes like potassium, magnesium, and calcium.
      • Participants must be able to **take oral medication**.

Who cannot join the trial?

7 criteria

  • Patients who have a different type of tumor than Tenosynovial Giant Cell Tumor cannot participate. This is a specific type of tumor that affects the tissue around joints and tendons.
  • Patients who are not within the specified age range for the study cannot participate. The study is open to certain age groups only.
  • Patients who are not able to follow the study procedures or who have conditions that might interfere with the study results cannot participate.
  • Patients who are pregnant or breastfeeding cannot participate, as the study may involve risks to the baby.
  • Patients who have participated in another clinical trial recently may not be eligible, as this could affect the study results.
  • Patients with certain medical conditions that could interfere with the study or pose a risk to their health cannot participate.
  • Patients who are unable to provide informed consent, which means they cannot understand and agree to the study procedures, cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Vimseltinib is a medication being studied for its ability to reduce the size of tumors in patients with Tenosynovial Giant Cell Tumor. This trial aims to assess how well the medication works in shrinking tumors by using specific criteria to measure changes in tumor size.

What is already known about the treatment

Vimseltinib – Vimseltinib is administered orally and is currently being studied in clinical trials for its effectiveness and safety in treating Tenosynovial Giant Cell Tumor. It is in the investigational stage and not yet widely available in medical practice. The main therapeutic indication for vimseltinib is its potential to reduce tumor size in patients with this specific type of tumor. At the molecular level, vimseltinib works by inhibiting certain enzymes that are involved in the growth and survival of tumor cells. It is classified pharmacologically as a kinase inhibitor.

Investigated diseases

Tenosynovial Giant Cell Tumor – This is a type of non-cancerous tumor that affects the synovium, which is the lining of joints and tendons. It often occurs in the knee, hip, ankle, or fingers, leading to swelling and pain in the affected area. The tumor can grow slowly and may cause joint stiffness and reduced range of motion over time. Although it is not cancerous, it can cause significant discomfort and impair joint function. The condition may recur after treatment, necessitating ongoing monitoring. It is more common in adults and can vary in size and severity.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-513624-42-00Protocol codeDCC-3014-03-001Estimated enrolment123 patientsSponsorDeciphera Pharmaceuticals Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).